Table 4.
Adverse events during the nivolumab therapy
| All cases (n=95) | COPD (n=41) | non-COPD (n=54) | |
|---|---|---|---|
| Haematologic toxicity | |||
| Leucopenia | 2 (0)* | 1 (0) | 1 (0) |
| Neutropenia | 2 (0) | - | 2 (0) |
| Anemia | 10 (0) | 3 (0) | 7 (0) |
| Thrombocytopenia | 2 (0) | – | 2 (0) |
| Non-haematologic toxicity | |||
| ALT/AST increased | 4 (2) | 1 (1) | 3 (1) |
| Bilirubin increased | 1 (0) | - | 1 (0) |
| Creatinie increased | 4 (0) | 1 (0) | 3 (0) |
| Nausea/Appetite loss | 5 (1) | – | 5 (1) |
| Constipation | 2 (0) | – | 2 (0) |
| Diarrhea | 7 (4) | 3 (2) | 4 (2) |
| Fatigue | 8 (0) | 3 (0) | 5 (0) |
| Dysgeusia | 1 (0) | 1 (0) | - |
| Rash acneiform | 4 (1) | 2 (0) | 2 (1) |
| Dry skin | 3 (0) | 1 (0) | 2 (0) |
| Pneumonitis | 6 (0) | 3 (0) | 3 (0) |
| Lung infection | 4 (3) | 2 (2) | 2 (1) |
| Haemoptysis | 1 (0) | – | 1 (0) |
| Thromboembolic events | 1 (0) | – | 1 (0) |
| Hyperglycemia | 1 (1) | – | 1 (1) |
| Immune-rerated Adverse Events | |||
| Myositis | 1 (1) | – | 1 (1) |
| Type I Diabets Mellitus, Hyperglycemia | 1 (1) | – | 1 (1) |
| Hyperthyroidism | 1 (1) | 1 (1) | – |
| Hypothyroidism | 3 (1) | 3 (1) | – |
| Adrenal insufficiency | 1 (0) | 1 (0) | – |
Note: *Any (Grade ≥ III).